



## **Oramed Pharmaceuticals to Present at the 9th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2010**

***Oramed to present on Wednesday, June 16<sup>th</sup> at 11:50 a.m. (IDT)***

JERUSALEM, Israel – June 8, 2010 – Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB); [www.oramed.com](http://www.oramed.com)), a developer of oral delivery systems, today announced today that it was chosen to present at the 9th National Life Science & Technology Week ILSI-BIOMED Conference, Israel 2010. The presentation will be given by Nadav Kidron, Chief Executive Officer of Oramed, on Wednesday, June 16<sup>th</sup> during the BioPharma Session at 11:50 a.m. (IDT) at the David Intercontinental Hotel in Tel-Aviv, Israel.

**Event:** National Life Science & Technology Week ILSI-BIOMED Conference, Israel 2010

**Date:** Wednesday, June 16 2010

**Time:** 11:50 a.m. (IDT), or 4:50 a.m. (EST)

For more information about the upcoming ILSI Biomed conference, please visit the following website:

<http://www2.kenes.com/biomed/Pages/Home.aspx>

### **About Oramed Pharmaceuticals**

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in Phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research performed by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.

For more information, please visit <http://www.oramed.com>.

### **Safe Harbor Statement**

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry

results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements.

**Company and Investor Relation Contacts:**

Oramed Pharmaceuticals Inc.

Tara Horn

Office: 646-240-4193

Cell: +972-54-334-4318

Email: tara@oramed.com